shutterstock-163310765-3

Andy P / Shutterstock.com

30 May 2014Europe

Imanova: investing in know-how

Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Dexcom suffers second patent revocation at hands of UPC

Does the UPC offer a fresh take on patent validity?

UK firm prevails in ‘exceptionally slow’ UPC test case

Litigation implications of the USPTO’s terminal disclaimer proposal

‘Still on the outside’: UPC says Abbott PI not valid in Ireland

Technical prejudice in support of inventive step: A double-edged sword?

‘Masking only works for so long’: Working with ADHD

Attorney v examiner: Navigating patenting's AI tools ‘arms race’